| Positive Rankings |
Estimated Revenue Growth
La Jolla Pharmaceutical Company rank is 42 |
Highest Cash Growth
La Jolla Pharmaceutical Company rank is 347 |
Up EPS Surprise
La Jolla Pharmaceutical Company beat the consensus earnings estimate when it last reported quarterly earnings. |
| Negative Rankings |
Negative ROE
La Jolla Pharmaceutical Company rank is 54 |
Negative MACD Cross
The MACD Divergence has recently become negative while the MACD remains positive. This is typically a negative short-term indicator. |
Negative Net Margin
La Jolla Pharmaceutical Company rank is 132 |
90 Day Loss
La Jolla Pharmaceutical Company rank is 176 |
Negative ROA
La Jolla Pharmaceutical Company rank is 255 |
Price-to-Sales
La Jolla Pharmaceutical Company rank is 309 |
Debt-to-Equity
La Jolla Pharmaceutical Company rank is 791 |
Price-to-Book
La Jolla Pharmaceutical Company rank is 853 |
High/Dropping MACD
The MACD remains positive, but is dropping... suggesting a possible near-term correction. Of companies with a positive, but declining MACD, La Jolla Pharmaceutical Company is ranked 1025. |
High vPut/Call
La Jolla Pharmaceutical Company has a high Put/Call ratio of 0.90 on active options expiring within the next 90 days. A high put-to-call ratio indicates there are more bearish investors than bullish investors for the stock. Among companies with a high Put/Call Ratio, La Jolla Pharmaceutical Company is ranked 1437. |
High Put/Call
La Jolla Pharmaceutical Company has a high Put/Call ratio of 0.68 on all open interest of options expiring in the next 90 days. A high put-to-call ratio indicates there are more bearish investors than bullish investors for the stock. Among companies with a high Put/Call Ratio, La Jolla Pharmaceutical Company is ranked 1444. |
10 Day Loss
La Jolla Pharmaceutical Company rank is 1459 |
